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Imaginary Worlds and Efficiency Frontiers: Should We Abandon the IQWiG Health 
Technology Assessment Model? 
Paul C Langley, PhD, Adjunct Professor, University of Minnesota 
 
Abstract 
The contribution of cost-effectiveness analysis to the pricing of pharmaceuticals in Germany is at best marginal and in many, if not 
most cases, absent. While this may reflect a reasonable belief that cost-effectiveness analysis adds little if anything to pricing and 
formulary placement decisions, its marginalization reflects considerable dissatisfaction, if not frustration, with modeling efforts by the 
Institut für Qualität und Wirtschaftlichkeit im Gesundheitseesen (IQWiG). In part, this reflects the rejection of quality adjusted life years 
(QALYs) as the common outcome standard, together with the adoption of the efficiency frontier as the default framework for modeled 
claims.  The purpose of this commentary is to consider the merits, in the German context, of an efficiency frontier framework for cost-
effectiveness and pricing decisions. The commentary concludes that the efficiency frontier framework for health technology 
assessment, in supporting the creation of non-evaluable claims from models or simulations, fails of to meet the standards of normal 
science: it fails to support claims that are credible, evaluable and replicable. It should be abandoned. If cost-effectiveness modeling is 
to play a constructive role in pricing negotiations in Germany then manufacturers should be required to submit evaluable claims. The 
most effective way of ensuring this is to require manufacturers to accompany any submission for a new product with a protocol 
detailing how their claims, to include those for clinical outcomes, cost-effectiveness and budget impact, are to be evaluated and 
reported to decision makers in a meaningful time frame.  
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Introduction 
Over the past 25 years recommendations and standards for 
assessing the merits of competing health care interventions 
have focused models or simulations that are intended to 
‘inform’ decision makers through the construction of 
imaginary worlds 1. In the past nine months, a number of 
commentaries have been published in INNOVATIONS in 
Pharmacy pointing to the lack of scientific merit in this 
approach to the economic evaluation of claims for 
pharmaceutical products and devices. These commentaries 
include reviews of technology assessment standards in the US, 
UK, Ireland, New Zealand, Australia, the Netherlands and 
France, together with the proposed European Union standards 
under the EUnetHTA umbrella 2 3 4 5 6 7 8 9. A common feature 
of these guidelines is the adoption of the National Institute for 
Health and Care Excellence (NICE) reference case which 
focuses on the ‘gold standard’ of constructing non-evaluable 
claims for competing pharmaceutical products in terms of 
cost-per-quality adjusted life years (QALYs). The typical   
reference case   framework for  
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chronic disease is a modeled or simulated lifetime (or long-
term) tracking of the natural course of the disease for a 
hypothetical patient cohort. Adoption of a reference case or 
similar framework that focuses on lifetime models is in 
contrast to the standards of normal science. As stated in the 
draft for the latest Canadian guidelines:  Economic evaluations 
are designed to inform decisions. As such, they are distinct 
from conventional research activities, which are designed to 
test hypotheses 10. Unfortunately, as pointed out on a number 
of occasions in the previous commentaries, building 
simulations to ‘inform decisions’ is hardly an acceptable basis 
for formulary decision making as we have no idea whether the 
constructed claims are right or even if they are wrong 11 12. In 
short, the commentaries have pointed out that outcomes for 
competing therapies expressed over the long-term or a 
lifetime means that the claims made are not credible, 
evaluable or replicable 13 14 15 16 17 18 19 20. They are best seen 
as pseudoscience sharing the platform with intelligent design 
rather than natural selection 21.  
 
Although they are the preferred ‘end-point’ in many, if not the 
majority of technology assessment guidelines, QALYs have 
come in for increasing criticism over the last few years. Apart 
from ethical issues, there have been concerns expressed over 
the methodological foundations for QALY claims, the number 
of competing QALY instruments, differences in the process of 
utility evaluation and their lack of sensitivity, and an outright 
rejection of their use in claims for certain formulary decisions 
in the US under the Patient Protection and Affordable Care Act 
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                        2017, Vol. 8, No. 1, Article 13                         INNOVATIONS in pharmacy   2 
 
22 23. In Germany the Institut für Qualität und Wirtschaftlichkeit 
im Gesundheitseesen (IQWiG Institut für Qualität und 
Wirtschaftlichkeit im Gesundheitseesen (IQWiG), as detailed 
below, has rejected QALYs as a ‘gold standard’ of comparative 
effectiveness  in its ‘General Methods’ for health technology 
assessment 24. Rather, the focus is on disease specific therapy 
measures. There is no single preferred measure in specific 
disease states; rather, there is the flexibility, within the 
efficiency frontier methodology to generate maximum 
reimbursable prices for individual effectiveness measures.  
Under the efficiency frontier methodology total benefits are 
compared to total costs rather than applying incremental cost-
effectiveness ratios (ICERs).  The principal reason for this 
rejection, although a case can be made that if QALYs are seen 
as an international standard then Germany should follow suit, 
is that there are competing constitutional rights and legal 
restrictions. These prevent the application of cost-per-QALY 
ratios together with thresholds for pricing and out-of-pocket 
payment assessments. There may also be cultural reasons for 
an efficiency frontier with a ‘reluctance to frame healthcare 
decisions around cost-based valuations of human health’ and 
their potential implications for health care rationing 25. 
Unfortunately, as noted below, even if QALYs are rejected, the 
same objections apply if alternative outcomes are modeled in 
a long-term or lifetime framework. They still fail to meet the 
standards for normal science.  
 
The purpose of this commentary is to consider the merits, in 
the German context, of an efficiency frontier framework for 
cost-effectiveness and pricing decisions. The principal focus is 
on the need to create a health technology assessment 
framework that supports credible and evaluable claims for 
anticipated impact of a new product in German target patient 
populations. Technology assessment standards should be 
consistent with the standards for hypothesis testing that 
characterize normal science. If technology assessment 
standards, such as those proposed by IQWiG fail this test then 
they should be rejected.  
 
Price Determination in Germany 
There are three agencies involved in price negotiations with 
manufacturers in Germany. These are: (i) The Federal Joint 
Committee (Gemeinsamer Bundesausschuss, GBA); (ii) IQWiG; 
and (iii) The National Association of Statutory Health Insurance 
Funds (SFI). Under the 2011 Pharmaceutical Market 
Reorganization Act (AMNOG) cost-effectiveness analysis has 
been put to one side from its previous central role as providing 
a framework for determining maximum reimbursable prices 
under the IQWiG umbrella. The current regulations require the 
negotiation of new drug prices to be informed by a 
comparative clinical effectiveness benefit assessment by 
IQWiG. The remit for IQWIG is to determine whether a 
manufacturer’s dossier has made the case that a new drug 
provides added net patient-relevant benefit, including health 
status improvement, shortening disease duration, life 
expectancy extension, alleviation of side effects or improved 
quality of life. The product is then categorized by IQWiG as 
providing a major, considerable or minor benefit. 
 
Cost-effectiveness considerations are only introduced if there 
is a failure to achieve a negotiated price. These take place 
under two scenarios: (i) an assessment of submitted dossiers 
and (ii) a commissioned health economics evaluation. Both 
scenarios are initiated by the GBA and undertaken by IQWiG 
as two of its product-specific procedures. The only scenario 
under which IQWiG considers price is where the GBA and the 
manufacturer co-ordinate and agree to IQWiG’s undertaking a 
cost-effectiveness assessment. Otherwise, IQWiG’s role is to 
assess the drug’s benefit. 
 
It should be noted that apart from the structured assessment 
process for new drugs the GBA has the authority under 
AMNOG to commission IQWiG to undertake assessments of 
existing medications and devices. This covers drugs that 
entered the German market before the 2011 reform and were 
not evaluated for net benefit as well as follow-up studies for 
drugs previously assessed. Manufacturers may also request a 
follow-up assessment. 
 
Comparative Effectiveness Assessment 
As noted, IQWIG’s role is to assess the added benefits a drug 
brings to the target population. This is achieved through 
evaluating a manufacturer’s submission to the GBA. This 
assessment may involve IQWiG undertaking its own literature 
search as well as soliciting external expert advice on the clinical 
benefits of a new product. The assessment should, hopefully, 
come to a clear conclusion as to whether or not the product 
contributes added benefits and harms for the individual 
patient. The key patient relevant outcomes are mortality, 
morbidity and health-related quality of life. A hierarchy of 
outcomes may be created with analyses focused on the higher 
weighted ones. 
 
 The term ‘benefit assessment’ refers to the ‘whole process of 
the assessment of medical interventions with regard to their 
positive and negative causal effects compared to a clearly 
defined alternative treatment, a placebo or no treatment’. 
Surrogate endpoints are considered unreliable and will only be 
considered if they have been appropriately validated.  
 
The term ‘harm’ refers to adverse events and which are an 
‘essential and equal component in the benefit assessment of 
an intervention’. Relevant adverse events include: (i) those 
that completely or almost completely offset the benefit of an 
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intervention’; (ii) vary substantially between two or more 
otherwise equivalent treatment options; (iii) occur 
predominantly in particularly effective treatment options; (iv) 
have a dose-effect relationship; (v) are regarded as particularly 
important by patients; and (vi) are accompanied by serious 
morbidity, increased mortality or substantial impairment in 
quality of life. 
 
Manufacturer Submission 
The benefit assessment of a drug starts from a dossier 
submitted by a manufacturer. The information provided 
should include: (i) approved therapeutic indication; (ii) medical 
benefit; (iii) likelihood of added medical benefit compared 
with appropriate comparator therapy: (iv) number of targeted 
patients and patient groups; (v) cost of treatment for the SRI; 
and (vi) requirements for quality-assured use of drug. The 
added benefit claimed in the dossier should be categorized as 
major, considerable, minor, non-quantifiable, no added 
benefit and benefit less than for comparator.   
 
Evidence Evaluation 
The IQWiG evidence evaluation considers what is described as 
both qualitative and quantitative certainty in results. The 
former is determined by an assessment of the study design and 
outcome related measures to avoid or minimize bias. The 
latter by effect size. Studies are classified as having high, 
moderate or low qualitative certainty of results. Depending 
upon the number of studies assessed together with an 
evaluation of study heterogeneity, the proof of evidence is 
determined for the benefit inferred for each patient-relevant 
outcome. If possible, a summary is presented in the form of a 
weighting of benefits and harms. There is the option of 
aggregating the various outcomes to a single measure. 
Supplementary information may be requested from the 
manufacturer, supported if necessary by a systematic 
literature review. 
 
IQWiG Modeled Efficiency Frontier 
The efficiency frontier was developed at the request of IQWiG 
as a method to inform decision makers of the net costs and 
additional benefits of an intervention given other 
interventions in the disease or therapy area 26.  Its purpose is 
to generate evidence to support negotiations for an 
acceptable reimbursable price. It is not IQWiG’s role to make 
recommendations as there is no evidence for the financial 
capacity of the SHI insurers or their willingness-to-pay. The 
efficiency frontier exercise is merely to provide information. 
There is no evidence of any intent to utilize the efficiency 
frontier as the basis for generating evaluable comparative 
claims for either clinical effect or cost-effectiveness. 
The modeled efficiency frontier is constructed for all available 
treatments for a given indication within a disease or therapy 
area. The frontier is constructed as a plane with health effects 
on the vertical axis and net costs on the horizontal. The effects, 
for example modeled lifetime outcomes for a hypothetical 
patient cohort, should meet cardinal measurement standards 
over the appropriate benefit range.  Treatment strategies that 
are not considered dominated are linked in ascending order of 
effectiveness. A maximum reimbursable price is determined as 
an input to total costs by the linearly extrapolated last segment 
of the frontier. This extrapolation establishes the same trade-
off for benefits and costs as the trade-off between the most 
efficient or effective intervention relative to the second most 
efficient. This establishes the ‘authorities’ implicit willingness-
to-pay for additional benefits in that indication. The 
reimbursable price is considered in the context of total costs 
that include proposed drug costs (which comprise the number 
of units by price proposed by the manufacturer) and other 
direct medical costs. The model can be extended to include 
non-medical costs such as productivity losses. 
  
There are no restrictions on the number of outcomes that 
could be identified within an indication. Where there are 
multiple end-points, clinical or patient reported, it is possible 
to create an aggregate efficiency frontier in relation to the net 
costs of the interventions. This translates to possible 
techniques to aggregate weighted outcomes to create this 
‘overall’ frontier.  
 
Each non-dominated intervention or efficient point on the 
frontier is constructed from a standard model for that 
indication. The modeled claims for benefits and net costs are, 
given the timeframe (see below) typically non-evaluable. 
Uncertainty in the models for each point on the frontier 
(including the new product) will reflect variations in its position 
on the cost-benefit plane.  
 
Discussion 
The comments and recommendations below should be seen 
alongside the current review of the IQWiG guidelines for a 
proposed Version 5.0 27.  Unfortunately, it was not possible to 
review the draft proposals as these are only available in 
German. The focus, therefore, is on Version 4.2.  
 
The IQWiG Model 
In common with other health technology assessment groups 
IQWiG requires a modeled claim to support product benefits. 
According to IQWiG in populating the efficiency frontier 
modeled estimates of each of the potential comparators are 
to be developed with their cost-effectiveness ratios. 
Presumably this means that the frontier should capture  cost-
effectiveness estimates of the new product, utilizing the 
identical model structure, together with those for the ‘less 
efficient’ ranked products The new product estimate should 
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include the proposed unit price, with existing market prices 
included in the modeled claims for the other non-dominated 
frontier product coordinates. If there are a number of 
efficiency frontiers constructed, then these should be 
weighted to generate an overall measure of overall benefit for 
these various products. Each of these, presumably, utilizing 
the common model structure. 
 
The development of a modeled claim is seen by IQWIG as the 
key component of a health technology assessment in 
extrapolating  benefits and costs beyond those generated by 
the studies used to support model assumptions. In practical 
terms, this can be interpreted as a preference for a long-term 
if not a lifetime modeling of costs and benefits. The principal 
objection to this hierarchy of modeled claims, where they are 
used to create an efficiency frontier of lifetime outcomes is 
that the claims for benefits and costs for each point on the 
frontier are imaginary. There is no basis for evaluating their 
merits. They fail to meet the standards for hypothesis testing. 
Modeled claims and simulations, of course, can always fail 28. 
Unfortunately, in IQWiG’s case the simulations driving the 
efficiency frontier are immune to failure. The only exceptions 
would be in end-stage disease states where the expected 
survival profile for the target population is short and 
potentially open to evaluation. There is no requirement that 
modeled claims for products already on the German market 
should be evaluated as validation for the efficiency frontier 
claim. 
 
In common with other health technology assessment 
guidelines, there appears to be no attempt by IQWiG to ask 
manufacturers to stand behind their claims for the new 
product. Irrespective of the dossier requirement for 
manufacturers to categorize the extent of intended benefit. 
Together with IQWiG’s possible reassessment of the 
appropriate benefit category, there is no apparent interest in 
the potential for claims evaluation, and indeed replication, in 
the target German populations. The possibility of feedback to 
decision makers is not considered as part of a possible program 
of ongoing disease area and therapeutic class reviews. Indeed, 
given the effort IQWIG apparently puts into determining the 
quality of the evidence base and the estimate and 
categorization of the effect size for each outcome as inputs to 
an overall assessment of an overall categorization of the added 
benefit of the drug, it is not clear why the issue of evaluation 
and replication in the target populations is not considered. As 
it stands these are constructed claims of added benefit, but we 
have no idea if these are right or even if they are wrong. The 
notion of progress through hypothesis testing or systematic 
observation of claims through comparative effectiveness 
assessments is absent.  
 
Comparators and Simplification 
In deriving the efficiency frontier, IQWiG requires ‘all 
healthcare-relevant interventions in the therapeutic area to be 
considered’. In this context, ‘considered’ means that each of 
the relevant interventions, not necessarily those that the new 
product is likely to supplant, should be modeled. Each of these 
models is seen as a ‘simplified depiction of reality’ with analytic 
clarity achieved by reducing complexity.  This ‘simplification’, 
IQWiG acknowledges, cannot be specified a priori, instead 
there should be agreement with experts to check on the 
models external validity. Presumably, as noted above, the 
model structure should be the same for each of the relevant 
interventions, where the modeled claims for benefits and net 
costs will determine whether or not comparators yield the 
greatest benefit in relation to costs (i.e., fall on the efficiency 
frontier).  
 
There is no requirement, as also noted above, even if the 
intervention has been on formulary for some years, for the 
modeled claim to have ever been evaluated in the target 
population. Indeed, the present modeled claim for an existing 
product may bear no resemblance in either its structure or 
parameter values to previous claims utilizing an alternative 
model by a different manufacturer. In effect, all the points on 
the efficiency frontier could represent interventions for which 
the claims are non-evaluable. The frontier, therefore, is an 
entirely imaginary construct. This situation is compounded 
where there might be a family of frontiers and an overall 
efficiency frontier is developed as a weighted average of these 
imaginary benefit and cost claims. 
 
Validation 
IQWiG points out that a simulation model that is valid for one 
research question might not be valid for another. Validation 
for IQWiG encompasses three elements: whether the model (i) 
adequately reflects the course of the disease and treatment; 
(ii) is technically correct; and (iii) generates predictive results 
that reflect the ‘real world’. While IQWiG recognizes that 
prediction is the ‘most desirable form of validity’, it points out 
that this is difficult (if not impossible) and falls back on 
proposing a comparison with previous modeled results. Given 
the apparent importance that IQWiG attaches to a model’s 
ability to generate credible predictions, it is surprising that 
IQWiG does not emphasize the importance of only recognizing 
models that generate credible and evaluable claims. As it 
stands, IQWiG would appear to accredit equal status to models 
that are capable of generating evaluable claims and those that 
generate claims that are immune to failure. This means that 
IQWiG is prepared to accept an efficiency frontier framework 
where the ‘efficient’ comparators claims are non-evaluable for 
the target German patient population.  
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Adherence and Persistence 
In common with other health technology assessment agencies 
IQWiG puts to one side any attempt to assess the potential 
impact on the modeled benefits of poor adherence and 
discontinuation of therapy. There is now ample evidence that 
for many if not most pharmaceuticals the majority of patients 
have discontinued therapy within two to three years of an 
index prescription. Adherence, for those remaining on therapy 
is also poor with low medication possession or days covered 
ratios. IQWiG’s standards for modeling benefits and costs take 
no account of anticipated compliance behavior or, indeed, of 
intervention strategies that may have accompanied 
comparator therapies to support compliance.   
 
Failure to take compliance behavior into account means that it 
is likely that the benefits attributed to the comparator 
products together with the modeled benefits from the new 
product will be overstated. Given the fact that the comparator 
therapies will have been on the market in Germany for some 
years, it would surely be possible to provide compliance data 
to modify modeled claims for chronic disease interventions. An 
assessment of product and comparator benefits, particularly in 
chronic disease, may be (at best) only short term once the 
implications of poor compliance behavior are taken into 
account. 
 
A further issue which is not considered by IQWiG and which is 
clearly relevant for adherence and persistence is the presence 
of comorbidities in the target population. The majority of older 
patients with chronic conditions will have one or more 
comorbidities. Failure to accommodate these in modeled 
claims casts further doubt on the model’s  relevance. 
 
Uncertainty 
Three types of uncertainty are typically considered in decision 
models: stochastic, parameter and structural. IQWiG 
recognizes these and requires modeled claims to address 
these issues both for individual outcome-specific models as 
well as for overall benefit assessments. In attempts to defend 
the viability of modeled claims, considerable effort has gone 
into developing techniques to capture the impact of 
uncertainty in the claims that accompany, for example, 
lifetime cost-per-QALY claims under the NICE reference case 
model. While these have a possible theoretical interest, their 
practical benefit is difficult to see given that the underlying 
construct is still an imaginary world. Of course, where 
competing models may come to quite different conclusions for 
the impact of new therapies in disease areas there seems little 
scope for assessing the various models outside of evaluable 
claims.  
 
These arguments also apply to attempts to model uncertainty 
for efficiency frontiers. A recent attempt to model the effect 
of parameter uncertainty utilizing a Monte Carlo simulation to 
create scatter plots, confidence intervals and contour plots 
together with the construction of price acceptability curves 
(PACs), illustrates the limitation of this for decision-making 29. 
Apart from the imaginary nature of the final PAC construct, it 
is far from clear how decision makers would interpret this and 
which interquartile range would be selected as input to pricing 
negotiations. 
 
Replication of Results 
Even though IQWiG may undertake a comprehensive 
systematic review of the relevant literature to assess the likely 
effect size for the competing interventions, there are 
recognized limitations to accepting claims for comparative 
effects from indirect comparisons. More to the point, there 
have been increasing concerns over the ability to replicate 
phase 2 and phase 3 randomized clinical trial (RCT) results 30. 
This puts increased emphasis on asking manufacturers to 
underwrite protocols to evaluate claims made for treatment 
effect and adverse effect profiles. These, as noted below 
should be an integral part of a protocol to establish claims for 
cost-effectiveness in the target patient population. The issue 
of replication of clinical effect claims in German treatment 
populations does not appear in the IQWiG guidelines.  
 
IQWiG’s categorization of a drug product as of major benefit 
across the range of outcomes considered just simply sets the 
stage for providing credible claims, evaluating the claims and 
replicating those claims in target patient populations. 
Evaluating those claims should be a necessary next step. 
 
Efficiency Frontier Redundancy 
Irrespective of the contribution of efficiency frontiers to 
portfolio management models, the application of the notion of 
an efficiency frontier adds little if anything to the framework 
for the competing assessment of drug therapies. While there 
is no doubting the visual appeal of a frontier representation, it 
needs to be kept in mind that the frontier is simply an 
imaginary construct. There may in fact be a family of imaginary 
efficiency frontiers, each relying upon constructed evidence 
for the potential outcomes identified from the reviews of RCTs 
and supplementary literature searches. There is also, 
apparently, a ‘master’ imaginary frontier which is a weighted 
aggregate of the individual efficiency frontiers. The weighting 
criteria are unknown as are the measurement properties of 
this putative health benefit index.  
 
This does not mean that it is not impossible to construct 
imaginary lifetime models utilizing the efficiency frontier 
concept. A recent paper by Gissel et al applied the efficiency 
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frontier method to the impact of direct-acting retrovirals in 
Hepatitis C in Germany  31. A lifetime Markov framework was 
developed to simulate immediate treatment effect (up to 72 
weeks) in sustained virologic response (SVR) as well as the 
impact on possible long-term complication costs associated 
with disease progression across a range of single therapy and 
combination therapy options. While the long-term claims are 
obviously not evaluable and should be put to one side, there is 
the potential within the model to evaluate short term SVR and 
associated costs and to generate evaluable claims that can be 
assessed and reported to decision makers in a meaningful time 
frame. The critical question is whether or not it is possible to 
defend empirically a reference marginal efficiency frontier cost 
(e.g., cost per additional SVP percentage point increase) to 
establish the threshold values for evaluating the cost 
consequences of new products and recommendations for 
pricing and possible rebates. Clearly, if a reference point 
willingness-to-pay as determined by previously negotiated 
prices for products in the disease area yields a commonly 
agreed marginal willingness to pay for unit or percentage point 
improvements in health outcomes, then these can be applied 
to claims that have been empirically assessed. It becomes a 
simple exercise to apply the willingness to pay amounts to the 
short term clams assessments. Unfortunately, we may have 
doubts as to the empirical base on which the previous prices 
were negotiated; a situation which is further confounded by a 
possible lack of agreement on what is considered the ‘primary’ 
outcome standards within specific disease areas. 
 
Systematic Price Increases 
A further issue, which has been touched upon in previous 
commentaries, is the currency of a simulated or modeled 
claim. Presenting competing claims in the framework of a 
lifetime reference case cost-per-QALY model raises the 
question of how to accommodate potential price increases for 
drug products and devices if the exercise is to generate claims 
that ‘meet’, for example, lifetime willingness-to-pay cost-per-
QALY thresholds. In the US, for example, models developed by 
the Institute for Clinical and Economic Review (ICER) exclude 
any attempt to factor in possible long-term price increases 32. 
Even if the NICE lifetime reference case paradigm is accepted 
by decision makers, the absence of modeling potential price 
increases restricts the currency of any argument that the 
product meets willingness-to-pay thresholds. It flies in the face 
of abundant evidence that, even with clams for moderation in 
price increases and, in the US in particular, policies to offer 
discounts or free access to offset co-payments, manufacturers 
are committed to a policy of systematic price increases over 
the patent life of a product 33 . These price increases, semi-
annual and annual, are all too often in double digits which 
means that within five or six years the product price, putting 
to one side possible discounting arrangements, is doubled. To 
the extent that, in Germany, there are anticipated price 
increases then these need to be factored into any assessment 
of future costs. 
 
Minnesota Proposed Guidelines 
Rather than focusing on the construction of imaginary worlds 
as an input to pricing negotiations, the solution proposed here 
is for IQWiG to mandate claims based on short term models; 
models than can generate claims that are credible, evaluable 
and replicable, and as a result, provide the opportunity for 
feedback to decision makers in a meaningful time frame. In 
order to illustrate how this could be implemented, the 
Program in Social and Administrative Pharmacy at the 
University of Minnesota, has published a set of proposed 
guidelines for formulary committees 34 35. These set standards 
for modeled claims, either as extrapolations from clinical trials 
or as stand-alone models, which can be evaluated within a 
two-year time frame. The key requirement is that submissions 
for new products should be accompanied by a protocol 
detailing how the claims are to be evaluated and reported to a 
formulary committee. It is responsibility of the manufacturer 
to underwrite the study design or to report on the results of a 
parallel study that may have been undertaken as part of 
another submission. There is no restriction on the type of claim 
as long as it is evaluable and is acceptable to the formulary 
committee. The claim can be expressed in utility as well as 
clinical effectiveness terms. Unless the timeframe for disease 
survival is short (e.g., in metastatic cancer interventions) 
claims expressed in lifetime or long-term cost-per-QALY or 
cost-per-life year saved would not be considered credible.  
 
There are, in fact, instances of short-term models that have 
been published over the last few years 36 37. These short term 
models which in these instances, consider the effectiveness of 
biologic treatments in rheumatoid arthritis in a Spanish target 
population and percutaneous coronary interventions in a 
French target population demonstrate the ease of 
constructing short-term models with evaluable claims.  
 
Options for GBA, SRI and IQWiG 
If the proposition is accepted that competing claims in 
Germany for the added benefits and potential harms of drug 
products should be credible, evaluable and replicable, then 
there are a number of options that could be considered for 
Version 5 of the IQWiG ‘General Methods’. These include 
requirements that:   
 
• The focus should be on short-term evaluable claims 
that can be assessed and reported back to health care 
decision makers in a meaningful (e.g., under two 
year) time frame. Long-term or lifetime modeled 
claims should be rejected. The claim submission, 
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following the proposed Minnesota guidelines for 
formulary evaluation, should be accompanied by a 
protocol detailing how claims are to be evaluated and 
reported to IQWiG, the GBA and the SFI. The protocol 
would be required to be agreed between the parties. 
The protocol should be comparative, identifying the 
product (or possibly products) most like to be 
replaced in clinical practice in the target treating 
population.   
 
• Rather than accommodating any number of potential 
outcome measures within a disease or therapy area, 
IQWIG should agree with the GBA, SFI and 
professional groups on a primary outcome measure. 
This could be related to the stage of the disease and 
linked to care pathways (e.g., median survival for 
metastatic cancers). This would not exclude the 
identification of what may be described as secondary 
outcome measures. Manufacturers would then be 
informed that in developing modeled claims for the 
product and comparators, the model should be 
developed to generate evaluable claims for the 
primary outcome. This would serve two purposes; (i) 
it would provide a focus for the development of a 
claims assessment protocol that would be 
underwritten by the manufacturer and (ii) it would 
avoid having to generate weighted aggregate claims 
across the various outcome measures that may be 
considered appropriate to the disease area. The 
claims protocol could, of course, accommodate 
secondary outcome measures.  
 
• In the absence of a report on the results of the 
protocol assessment for the modeled primary claim, 
any interim pricing negotiation should take as the 
reference point the existing unit prices for the 
respective comparator (e.g., the product most likely 
to be replaced in clinical practice). Multiple 
comparisons, particularly for those products deemed 
less ‘efficient’, are an unnecessary burden for both 
manufacturers and assessment agencies. A final price 
determination would then occur once the protocol 
results were available for the target population in 
Germany. This would reflect the assessed 
comparative benefits and costs, as well as the 
potential impact on these of compliance behavior.   
 
• The concept of an efficiency frontier should be 
abandoned. IQWiG should adopt a simpler and more 
robust approach to evaluating the benefits and costs 
from products entering the market. Attempting to 
populate one or more efficiency frontiers and 
aggregating across these with multiple criteria 
decision analysis (MCDA) or some variant of conjoint 
analysis is unnecessary and, from a price negotiation 
perspective, an irrelevant exercise. Attempting to 
agree, for example, on the elements of a MCDA and 
then the preference weights to be attached when so 
many parties are involved is unrealistic.  
Impractical and irrelevant. 
 
• Any attempt to re-introduce long-term or lifetime 
cost-per-QALY models and thresholds should be 
avoided. This does not mean that primary claims 
expressed as QALYs should be put to one side. While 
there may be substantive objections in Germany to 
QALYs and thresholds as rationing criteria, there is no 
reason why evaluable claims expressed in terms of a 
specific QALY instrument, or other patient reported 
outcome (PRO) measure specific to a disease or 
therapy area should not be accepted in prospective 
assessments of short-term claims. 
 
• A short-term model should accommodate 
uncertainty, but only as it is predicted to impact the 
claims made. Proposed study designs to evaluate 
claims, whether they are for a phase 4 trial design or 
a systematic observational study would be expected 
to meet the standards for evidence based medicine. 
This will avoid, in the focus on evaluable claims, 
attempts to assess the impact of uncertainty in 
models which are not designed to generate evaluable 
claims and further attempts, in the case for example 
of parameter uncertainty, imaginary price 
reimbursement acceptability curves. 
Conclusions 
Whether the GBA, SFI and IQWiG have any interest in a 
formulary evaluation program that meets the standards of 
normal science is a moot point. The options considered here 
provide a simpler and more direct approach to assessing the 
value of new products rather than trying to continue to 
support the application of efficiency frontiers. While the 
efficiency frontier has some interest as a theoretical concept, 
it is not a viable practical tool for pricing and formulary 
decisions, particularly when the focus is on constructing 
evaluable claims. Abandoning the efficiency frontier will bring 
to the fore a commitment to disease and therapeutic area 
strategies that support a commitment to progress and 
feedback in health care interventions. Rather than relying on 
imaginary constructs, the approach proposed here will create 
an evidence base that is of benefit to target patient 
populations.   
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